安旭生物(688075)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688075 安旭生物

已收盘 11-19 15:00:00

{"stockData":{"symbol":"688075","market":"SH","secType":"STK","nameCN":"安旭生物","latestPrice":41.55,"timestamp":1731999600000,"preClose":39.97,"halted":0,"volume":2095279,"delay":0,"floatShares":127000000,"shares":127000000,"eps":0.7122,"marketStatus":"已收盘","marketStatusCode":5,"change":1.58,"latestTime":"11-19 15:00:00","open":40.3,"high":41.6,"low":39.52,"amount":85632000,"amplitude":0.052,"askPrice":41.55,"askSize":2,"bidPrice":41.54,"bidSize":20,"shortable":0,"etf":0,"ttmEps":0.7122,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732066200000},"adr":0,"adjPreClose":39.97,"symbolType":"stock_kcb","openAndCloseTimeList":[[1731979800000,1731987000000],[1731992400000,1731999600000]],"highLimit":43.97,"lowLimit":35.97,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":127082805,"pbRate":1.03,"roa":"--","roe":"2.62%","epsLYR":1.11,"committee":0.055432,"marketValue":5280000000,"floatMarketCap":5280000000,"peRate":58.340355,"changeRate":0.0395,"turnoverRate":0.0165,"status":0,"afterMarket":{"amount":0,"volume":0,"close":41.55,"buyVolume":0,"sellVolume":0,"time":1732001639464,"indexStatus":"已收盘 11-19 15:30:00","preClose":39.97}},"requestUrl":"/m/hq/s/688075","defaultTab":"news","newsList":[{"id":"2484611566","title":"安旭生物11月18日获主力加仓914万元 环比增加975.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484611566","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484611566?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:19","pubTimestamp":1731914369,"startTime":"0","endTime":"0","summary":"11月18日, 安旭生物股价涨5.85%，报收39.97元，成交金额1.09亿元，换手率2.13%，振幅8.79%，量比3.03。安旭生物今日主力资金净流入914万元，上一交易日主力净流入85万元，今日环比增加975.29%。|11月18日主力加仓幅度前10个股||#|股票简称|主力净额占比|#|鼎龙科技|6.83%|#|好想你|3.74%|#|硅宝科技|3.22%|#|大东方|2.84%|#|朗威股份|2.83%|#|新乡化纤|2.75%|#|华盛锂电|2.65%|#|水发燃气|2.60%|#|和胜股份|2.58%|#|阳光股份|2.27%|安旭生物所在的医疗器械行业，今日主力净流出4.41亿元，行业排名22/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118153151a242269c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118153151a242269c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688075"],"gpt_icon":0},{"id":"2484633726","title":"安旭生物（688075）9531.2万股限售股将于11月18日解禁，占总股本75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484633726","media":"证券之星","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484633726?lang=zh_cn&edition=full","pubTime":"2024-11-18 08:02","pubTimestamp":1731888165,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，安旭生物于11月18日将有9531.2万股限售股份解禁，为公司首发原股东限售股份，占公司总股本75.0%。最近一年内，该股累计解禁127.08万股，占总股本的1.0%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111800001168.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688075"],"gpt_icon":0},{"id":"2482410719","title":"安旭生物9531万股限售股将于11月18日上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2482410719","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482410719?lang=zh_cn&edition=full","pubTime":"2024-11-12 11:02","pubTimestamp":1731380520,"startTime":"0","endTime":"0","summary":"安旭生物发布首次公开发行部分限售股上市流通公告。本次股票上市流通总数为9531万股，占公司总股本的75.00%。限售股上市流通日期定为2024年11月18日。此次上市流通的限售股形成后，公司未发生其他导致股本数量变化的事项。此外，控股股东及其关联方不存在资金占用情况，所有股东均已严格履行股份锁定承诺。2024年前三季度，安旭生物实现收入4.03亿元，归母净利润1.36亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112111115abb7e48a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112111115abb7e48a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688075","BK0239"],"gpt_icon":0},{"id":"2482066822","title":"安旭生物(688075.SH)：9531.2万股限售股将于11月18日起上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2482066822","media":"智通财经","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482066822?lang=zh_cn&edition=full","pubTime":"2024-11-11 18:21","pubTimestamp":1731320498,"startTime":"0","endTime":"0","summary":"智通财经APP讯，安旭生物(688075.SH)发布关于首次公开发行部分限售股上市流通公告，本次上市流通的限售股总数为9531.2万股，占公司总股本的75%，上市流通日期为2024年11月18日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688075"],"gpt_icon":0},{"id":"2481146968","title":"安旭生物11月08日遭主力抛售378万元 环比增加740.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481146968","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481146968?lang=zh_cn&edition=full","pubTime":"2024-11-08 15:19","pubTimestamp":1731050343,"startTime":"0","endTime":"0","summary":"11月08日, 安旭生物股价涨0.02%，报收40.52元，成交金额2965万元，换手率2.30%，振幅2.37%，量比0.73。安旭生物今日主力资金净流出378万元，上一交易日主力净流出45万元，今日环比增加740.00%。该股近5个交易日上涨6.30%，主力资金累计净流出1067万元；近20日主力资金累计净流出3594万元，其中净流出天数为16日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108153615abacba81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108153615abacba81&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688075"],"gpt_icon":0},{"id":"2480375462","title":"安旭生物(688075.SH)半年度每股派0.4元 股权登记日为11月8日","url":"https://stock-news.laohu8.com/highlight/detail?id=2480375462","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480375462?lang=zh_cn&edition=full","pubTime":"2024-11-04 16:37","pubTimestamp":1730709429,"startTime":"0","endTime":"0","summary":"智通财经APP讯，安旭生物(688075.SH)发布公告，公司将实施2024年半年度权益分派，每股派发现金红利0.4元(含税)，股权登记日为11月8日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1206266.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688075","BK0239"],"gpt_icon":0},{"id":"2479746577","title":"安旭生物(688075)9月30日股东户数0.67万户，较上期减少2.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479746577","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479746577?lang=zh_cn&edition=full","pubTime":"2024-10-31 17:10","pubTimestamp":1730365839,"startTime":"0","endTime":"0","summary":"证券之星消息，近日安旭生物披露，截至2024年9月30日公司股东户数为6697.0户，较6月30日减少152.0户，减幅为2.22%。在医疗器械行业个股中，安旭生物股东户数低于行业平均水平，截至9月30日，医疗器械行业平均股东户数为2.03万户。从股价来看，2024年6月30日至2024年9月30日，安旭生物区间涨幅为19.99%，在此期间股东户数减少152.0户，减幅为2.22%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100033750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688075"],"gpt_icon":0},{"id":"2479758217","title":"图解安旭生物三季报：第三季度单季净利润同比增1.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479758217","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479758217?lang=zh_cn&edition=full","pubTime":"2024-10-31 01:57","pubTimestamp":1730311037,"startTime":"0","endTime":"0","summary":"证券之星消息，安旭生物2024年三季报显示，公司主营收入4.03亿元，同比上升27.56%；归母净利润1.36亿元，同比下降27.33%；扣非净利润1937.89万元，同比下降80.45%；其中2024年第三季度，公司单季度主营收入1.55亿元，同比上升38.78%；单季度归母净利润2046.47万元，同比上升1.99%；单季度扣非净利润49.39万元，同比上升4408.83%；负债率11.21%，投资收益8757.91万元，财务费用662.28万元，毛利率42.11%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100003022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688075"],"gpt_icon":0},{"id":"2479078853","title":"安旭生物(688075.SH)发布前三季度业绩，净利润1.36亿元，同比下降27.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479078853","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479078853?lang=zh_cn&edition=full","pubTime":"2024-10-30 21:23","pubTimestamp":1730294585,"startTime":"0","endTime":"0","summary":"智通财经APP讯，安旭生物(688075.SH)发布2024年第三季度报告，公司前三季度营业收入4.03亿元，同比增长27.56%;归属于上市公司股东的净利润1.36亿元，同比下降27.33%;归属于上市公司股东的扣除非经常性损益的净利润1937.89万元，同比下降80.45%;基本每股收益1.07元/股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1204195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688075"],"gpt_icon":0},{"id":"2474656660","title":"安旭生物(688075.SH)授出119.5万股限制性股票 授予价17.32元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2474656660","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474656660?lang=zh_cn&edition=full","pubTime":"2024-10-11 17:51","pubTimestamp":1728640309,"startTime":"0","endTime":"0","summary":"智通财经APP讯，安旭生物(688075.SH)公告，公司于2024年10月11日召开的第二届董事会第十五次会议、第二届监事会第十三次会议，审议通过了《关于向2024年限制性股票激励计划激励对象首次授予限制性股票的议案》，《杭州安旭生物科技股份有限公司2024年限制性股票激励计划(草案)》规定的限制性股票授予条件已经成就，公司董事会确定2024年限制性股票激励计划的首次授予日为2024年10月11日，以17.32元/股的授予价格向符合授予条件的51名激励对象授予限制性股票119.50万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1192877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688075"],"gpt_icon":0},{"id":"2474037825","title":"安旭生物大跌5% 主力净流出481万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2474037825","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474037825?lang=zh_cn&edition=full","pubTime":"2024-10-11 14:09","pubTimestamp":1728626953,"startTime":"0","endTime":"0","summary":"10月11日，安旭生物股价大幅下跌，截至14点09分，安旭生物下跌5.00%，报36.10元/股，成交2686万元，换手率2.29%，振幅5.21%。资金动向截止发稿，安旭生物获得主力净流出481万元，其中超大单流出285万元，大单流出195万元。主营业务及业绩安旭生物公司主营业务为POCT试剂及仪器的研发、生产与销售。最新财报显示，今年中报，安旭生物实现营业收入2.48亿元，同比增长21.42%，净利润为1.15亿元，同比减少30.85%，基本每股收益为0.91元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241011141200a1dfe61b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241011141200a1dfe61b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688075","BK0239"],"gpt_icon":0},{"id":"2474278074","title":"安旭生物（688075）10月9日主力资金净卖出222.37万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2474278074","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474278074?lang=zh_cn&edition=full","pubTime":"2024-10-10 08:28","pubTimestamp":1728520095,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年10月9日收盘，安旭生物报收于38.48元，下跌11.07%，换手率5.74%，成交量1.82万手，成交额7321.7万元。近5日资金流向一览见下表：安旭生物融资融券信息显示，融资方面，当日融资买入780.77万元，融资偿还803.22万元，融资净偿还22.45万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101000009770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688075"],"gpt_icon":0},{"id":"2474265319","title":"安旭生物大跌5.02% 融资融券实现6连增","url":"https://stock-news.laohu8.com/highlight/detail?id=2474265319","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474265319?lang=zh_cn&edition=full","pubTime":"2024-10-09 09:30","pubTimestamp":1728437404,"startTime":"0","endTime":"0","summary":"10月09日，安旭生物股价大幅下跌，截至09点30分，安旭生物下跌5.02%，报41.10元/股，成交198万元，换手率0.15%，振幅0.12%。资金动向截止发稿，安旭生物获得主力净流出104万元，其中超大单流出126万元，大单流入23万元。融资融券方面，安旭生物10月08日获得融资净买入1156万元，当日该股融资余额为8827万元，当较前一日增加15.08%，实现6连增。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241009121944ab68b3e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241009121944ab68b3e9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688075"],"gpt_icon":0},{"id":"2473463623","title":"安旭生物创1年新高 医疗器械产业成绩显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2473463623","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473463623?lang=zh_cn&edition=full","pubTime":"2024-10-08 09:30","pubTimestamp":1728351001,"startTime":"0","endTime":"0","summary":"10月08日，安旭生物股价大幅上涨，截至09点30分，安旭生物上涨15.20%，报46.00元/股，创近1年新高，突破40元整数关口，成交351万元，换手率0.24%。资金动向截止发稿，安旭生物获得主力净流出146万元，其中超大单流出594万元，大单流入448万元。融资融券方面，安旭生物09月30日获得融资净买入35万元，当日该股融资余额为7670万元，当较前一日增加0.47%，实现5连增。主营业务及业绩安旭生物公司主营业务为POCT试剂及仪器的研发、生产与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241008100013ab683f4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241008100013ab683f4c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159883","688075","BK0239"],"gpt_icon":0},{"id":"2471815915","title":"安旭生物创7个月新高 融资融券实现3连增","url":"https://stock-news.laohu8.com/highlight/detail?id=2471815915","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471815915?lang=zh_cn&edition=full","pubTime":"2024-09-30 09:30","pubTimestamp":1727659810,"startTime":"0","endTime":"0","summary":"09月30日，安旭生物股价大幅上涨，截至09点30分，安旭生物上涨5.29%，报38.00元/股，创近7个月新高，成交196万元，换手率0.16%。资金动向截止发稿，安旭生物获得主力净流入715万元。融资融券方面，安旭生物09月26日获得融资净买入57万元，当日该股融资余额为7235万元，当较前一日增加0.80%，实现3连增。最新财报显示，今年中报，安旭生物实现营业收入2.48亿元，同比增长21.42%，净利润为1.15亿元，同比减少30.85%，基本每股收益为0.91元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240930095158ab66ed53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240930095158ab66ed53&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688075"],"gpt_icon":0},{"id":"2470978681","title":"安旭生物：9月26日召开业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2470978681","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470978681?lang=zh_cn&edition=full","pubTime":"2024-09-26 18:14","pubTimestamp":1727345649,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年9月26日安旭生物发布公告称公司于2024年9月26日召开业绩说明会。2023年度利润分配已于2024年7月顺利完成，合计派发现金红利50,833,122.00元。问：在近期公司发布的2024年限制性股票激励计划（草案）中及2024年至2026年的业绩考核目标为营收相比2023年分别增长25%、75%、153%。公司有望通过资源整合、深化技术合作以及实施精准的投资并购，稳步扩张在医学相关领域的业务版图，全面推动安旭生物向医疗大健康产业的转型与升级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092600028742.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688075"],"gpt_icon":0},{"id":"2470225073","title":"安旭生物大幅上涨 获主力净流入289万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2470225073","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470225073?lang=zh_cn&edition=full","pubTime":"2024-09-26 10:35","pubTimestamp":1727318147,"startTime":"0","endTime":"0","summary":"09月26日，安旭生物股价大幅上涨，截至10点35分，安旭生物上涨5.01%，报34.59元/股，成交1735万元，换手率1.61%，振幅4.52%。资金动向截止发稿，安旭生物获得主力净流入289万元，其中超大单流入238万元，大单流入50万元。融资融券方面，安旭生物09月24日获得融资净买入192万元，当日该股融资余额为7129万元，当较前一日增加2.78%。最新财报显示，今年中报，安旭生物实现营业收入2.48亿元，同比增长21.42%，净利润为1.15亿元，同比减少30.85%，基本每股收益为0.91元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240926103553a1dc99b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240926103553a1dc99b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688075"],"gpt_icon":0},{"id":"2470113474","title":"安旭生物创1个月新高 主力资金净流出81万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2470113474","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470113474?lang=zh_cn&edition=full","pubTime":"2024-09-25 09:30","pubTimestamp":1727227806,"startTime":"0","endTime":"0","summary":"09月25日，安旭生物股价大幅上涨，截至09点30分，安旭生物上涨6.46%，报34.60元/股，创近1个月新高，成交276万元，换手率0.25%，振幅2.46%。资金动向截止发稿，安旭生物获得主力净流出81万元，其中超大单流出96万元，大单流入15万元。主营业务及业绩安旭生物公司主营业务为POCT试剂及仪器的研发、生产与销售。最新财报显示，今年中报，安旭生物实现营业收入2.48亿元，同比增长21.42%，净利润为1.15亿元，同比减少30.85%，基本每股收益为0.91元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240925100935a1dc5722&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240925100935a1dc5722&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688075"],"gpt_icon":0},{"id":"2468482603","title":"安旭生物获得外观设计专利授权：“宠物生化检测盘片”","url":"https://stock-news.laohu8.com/highlight/detail?id=2468482603","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468482603?lang=zh_cn&edition=full","pubTime":"2024-09-17 02:16","pubTimestamp":1726510560,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示安旭生物新获得一项外观设计专利授权，专利名为“宠物生化检测盘片”，专利申请号为CN202330810608.0，授权日为2024年9月17日。今年以来安旭生物新获得专利授权14个，较去年同期减少了30%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024091700000560.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688075"],"gpt_icon":0},{"id":"2467430782","title":"安旭生物获得实用新型专利授权：“一次性末梢采血取血的装置”","url":"https://stock-news.laohu8.com/highlight/detail?id=2467430782","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467430782?lang=zh_cn&edition=full","pubTime":"2024-09-13 02:15","pubTimestamp":1726164912,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示安旭生物新获得一项实用新型专利授权，专利名为“一次性末梢采血取血的装置”，专利申请号为CN202322870099.8，授权日为2024年9月13日。今年以来安旭生物新获得专利授权13个，较去年同期减少了31.58%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024091300001954.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688075"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-11-18","address":"浙江省杭州市余杭区莫干山路1418-50号4幢3层(上城科技工业基地)","stockEarnings":[{"period":"1week","weight":0.0259},{"period":"1month","weight":0.1479},{"period":"3month","weight":0.2376},{"period":"6month","weight":0.2339},{"period":"1year","weight":-0.0248},{"period":"ytd","weight":0.0546}],"companyName":"杭州安旭生物科技股份有限公司","boardCode":"AI0027","perCapita":"18976股","boardName":"医药制造业","registeredCapital":"12708万元","compareEarnings":[{"period":"1week","weight":-0.0222},{"period":"1month","weight":0.0259},{"period":"3month","weight":0.1713},{"period":"6month","weight":0.0737},{"period":"1year","weight":0.0905},{"period":"ytd","weight":0.1247}],"survey":"　　杭州安旭生物科技股份有限公司专注于POCT试剂及仪器的研发、生产与销售。公司主要产品为POCT试剂及仪器。公司拥有抗原抗体自主研发生产的生物原料技术平台，以及成熟的免疫层析及干式生化诊断技术平台，发展形成了覆盖毒品检测、传染病检测、慢性病检测、妊娠检测、肿瘤检测、心肌检测、生化检测、过敏原检测八大领域的POCT试剂，产品远销美国、德国、英国、加拿大、俄罗斯、墨西哥、泰国、印尼及波兰等150多个国家，已成为国内少数几家在POCT国际市场能够与跨国体外诊断行业巨头竞争的中国体外诊断产品供应商之一。","serverTime":1732062243305,"listedPrice":78.28,"stockholders":"6697人(较上一季度减少2.22%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"安旭生物(688075)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供安旭生物(688075)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"安旭生物,688075,安旭生物股票,安旭生物股票老虎,安旭生物股票老虎国际,安旭生物行情,安旭生物股票行情,安旭生物股价,安旭生物股市,安旭生物股票价格,安旭生物股票交易,安旭生物股票购买,安旭生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"安旭生物(688075)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供安旭生物(688075)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}